These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22054917)

  • 1. Focusing on testosterone.
    Moul JW; Dreicer R
    Urology; 2011 Nov; 78(5 Suppl):S476-7. PubMed ID: 22054917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 5. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S; Yamazaki S; Kitamura T
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traditional approaches to androgen deprivation therapy.
    Moul JW; Evans CP; Gomella LG; Roach M; Dreicer R
    Urology; 2011 Nov; 78(5 Suppl):S485-93. PubMed ID: 22054920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
    [No Abstract]   [Full Text] [Related]  

  • 10. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective testosterone suppression for patients with prostate cancer: is there a best castration?
    Oefelein MG; Resnick MI
    Urology; 2003 Aug; 62(2):207-13. PubMed ID: 12893320
    [No Abstract]   [Full Text] [Related]  

  • 14. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8.
    Koupparis AJ
    Eur Urol; 2006 Sep; 50(3):626-7. PubMed ID: 16750291
    [No Abstract]   [Full Text] [Related]  

  • 16. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
    Kawamura K
    Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal therapy for advanced prostate cancer.
    Vaughn DJ
    Ann Intern Med; 2000 Apr; 132(7):584-5. PubMed ID: 10744596
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of advanced prostatic cancer].
    Hedlund PO
    Lakartidningen; 2000 Aug; 97(32-33):3466-9. PubMed ID: 11037588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.